Division of Reproductive Endocrinology, Department of Obstetrics Gynecology and Reproductive Science, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
Reproductive Medicine Associates of New Jersey, Basking Ridge, NJ, USA.
Trends Mol Med. 2014 Sep;20(9):499-508. doi: 10.1016/j.molmed.2014.06.006. Epub 2014 Aug 8.
Since its inception, in vitro fertilization (IVF) has pursued molecular technology to improve patient outcomes, leading to enhanced methods of embryo selection. Comprehensive chromosomal screening (CCS) is a powerful tool that decreases maternal and neonatal morbidity due to multiple gestations by allowing the transfer of fewer embryos while maintaining success rates. To optimize this genetic test, physiological principles limiting the timing and type of cells to be removed had to be realized. Molecular barriers involved in genome amplification and ensuring the accuracy and validity of the CCS platform required a multistep approach to ensure that this technology was not used prematurely. Only after ensuring that the potential for harm was minimized and benefit maximized could clinicians use this technology to improve patient care.
自成立以来,体外受精 (IVF) 一直致力于采用分子技术来改善患者的治疗效果,从而改进胚胎选择方法。全面染色体筛查 (CCS) 是一种强大的工具,它通过减少胚胎移植数量,同时保持成功率,降低了多胎妊娠导致的母婴发病率。为了优化这项基因检测,必须认识到限制去除细胞的时间和类型的生理原理。为了确保基因组扩增的分子障碍以及 CCS 平台的准确性和有效性,需要采取多步骤方法,以确保这项技术不会过早使用。只有在确保将潜在危害最小化并使获益最大化的情况下,临床医生才可以使用这项技术来改善患者的治疗效果。